Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7615
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:109
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism and digestive system, cardiovascular system, blood system, central nervous system drugs, anti-infection, anti-tumor, vaccine and raw material and intermediates. It provides medical diagnostic products such as real time PCR detector, human papillomavirus assay kit, HBV quantitative reagent, and biofosun microorganism identification and susceptibility analysis system. The company’s research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai City, Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Novartis May Sell US Generic Pill Business 19
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21
Venture Financing 22
Ambrx Raises USD45 Million in Venture Financing 22
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
Private Equity 26
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26
Partnerships 27
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29
Kite Pharma Forms Joint Venture with Fosun Pharma 30
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 32
Nature’s Sunshine Products Forms Joint Venture with Fosun Pharma 33
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35
Atrium Innovations Forms Joint Venture With Fosun Industrial 36
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39
Licensing Agreements 40
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial – Portela 40
Athenex to Enter into Licensing Agreement with Gland Pharma 41
Athenex to Enter into Licensing Agreement with Gland Pharma 42
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43
Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47
Equity Offering 48
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48
Gland Pharma May Raise USD500 Million in IPO 50
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51
Chindex to Raise USD38.2 Million in Private Placement of Shares 53
Phagelux Raises Funds through Private Placement 54
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58
Nature’s Sunshine Raises USD46 Million in Private Placement of Shares 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 61
Debt Offering 62
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68
Asset Transactions 69
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69
Acquisition 70
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 78
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 79
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Competitors 87
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Employees 88
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Recent Developments 91
Strategy And Business Planning 91
Nov 15, 2017: Fosun Pharma set up Suzhou R & D Center 91
Jul 11, 2017: Rooted in Shanghai innovation Fosun Pharma Zhangjiang new R & D headquarters base was officially launched 92
Financial Announcements 94
Mar 27, 2018: Fosun pharma: Announcement of Final Results for the Year Ended 31 December 2017 94
Oct 31, 2017: Fosun Pharma releases third quarter 2017 revenue up 21.83% YoY Research and development investment continues to increase 96
Aug 30, 2017: Fosun Pharma: R & D and international lighting performance, the first half revenue grew 20.41% 97
Jun 14, 2017: Fosun Pharma released first quarter 2017 revenue up 20.29% R & D investment continued to increase 99
Mar 31, 2017: Fosun Pharma non-net profit in 2016 increased by 26.36% year-on-year Continued to increase innovation and R & D investment Strengthen the layout of medical services 100
Corporate Communications 103
Mar 26, 2018: Change In Fosun Pharma’s Board Of Directors To Further Align Group Strategy 103
Mar 26, 2018: Shanghai Fosun Pharmaceutical Announces Personnel Changes 104
Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World’s Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 106
Product Approvals 108
Oct 29, 2017: Fosun Pharma treatment of leukemia new drug approved by the FDA drug clinical trials 108
Appendix 109
Methodology 109
About GlobalData 109
Contact Us 109
Disclaimer 109

List of Tables
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Novartis May Sell US Generic Pill Business 19
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21
Ambrx Raises USD45 Million in Venture Financing 22
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29
Kite Pharma Forms Joint Venture with Fosun Pharma 30
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 32
Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 33
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35
Atrium Innovations Forms Joint Venture With Fosun Industrial 36
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial - Portela 40
Athenex to Enter into Licensing Agreement with Gland Pharma 41
Athenex to Enter into Licensing Agreement with Gland Pharma 42
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43
Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48
Gland Pharma May Raise USD500 Million in IPO 50
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51
Chindex to Raise USD38.2 Million in Private Placement of Shares 53
Phagelux Raises Funds through Private Placement 54
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58
Nature's Sunshine Raises USD46 Million in Private Placement of Shares 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 61
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 78
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 79
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Competitors 87
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Employees 88
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Subsidiaries 90

List of Figures
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nuvaira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Nuvaira Inc (Nuvaira), formerly Holaira Inc is an independent medical device company that strives to develop minimally invasive products for the treatment of obstructive lung diseases. It provides Lung Denervation System, a catheter-based system intended for asthma and chronic obstructive pu …
  • Protea Biosciences Group Inc (PRGB)-医療機器分野:企業M&A・提携分析
    Summary Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for the characterization, identification, and quantitation of biologically-important molecules for research, pharmaceutical development, and diagnostic app …
  • Barton Malow Co:企業の戦略的SWOT分析
    Barton Malow Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • El Paso Electric Company (EE)-エネルギー分野:企業M&A・提携分析
    Summary El Paso Electric Company (El Paso) is a vertically integrated electric utility which generates, transmits, and distributes electric power. It produces electricity from nuclear, natural gas, coal, and solar sources. The company has ownership interest in and operates various power generation f …
  • Trimble Inc (TRMB):企業の財務・戦略的SWOT分析
    Trimble Inc (TRMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Red Hat Inc:企業の戦略的SWOT分析
    Red Hat Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Engie SA (ENGI)-エネルギー分野:企業M&A・提携分析
    Summary Engie S.A. (Engie), formerly GDF Suez S.A., is an electric utility, which generates and distributes electricity and natural gas. It generates electricity using various sources including hydro, wind, solar, biomass, geothermal, nuclear, coal and fuel oil. The company supplies, distributes, tr …
  • Distell Group Limited:戦略・SWOT・企業財務分析
    Distell Group Limited - Strategy, SWOT and Corporate Finance Report Summary Distell Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Zhejiang Hisun Pharmaceutical Co Ltd (600267):企業の財務・戦略的SWOT分析
    Summary Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) manufactures and commercializes drugs to treat tumor, infections, cardiovascular, endocrine, depression and orthopaedic disorders. The company’s product portfolio includes anti-tumor and anti-viral, hypoglycemic drugs, animal health products, oral …
  • American Municipal Power Inc:企業の発電所・SWOT分析2018
    American Municipal Power Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Oxford Nanopore Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Nanopore Technologies Ltd (Oxford Nanopore), formerly Oxford NanoLabs Ltd., develops disruptive, electronic, and single-molecule sensing system. The company’s products include SmidgION, Flongle, MinION, PromethION and GridION used for the analysis of DNA, RNA, proteins, small molecule …
  • OrthoPediatrics Corp (KIDS):医療機器:M&Aディール及び事業提携情報
    Summary OrthoPediatrics Corp (OrthoPediatrics) is a medical device company that designs, develops and distributes implants and instruments. The company offers trauma and deformity, spine, sports medicine, and clinical education products. It provides cannulated screws, spine system, ACL reconstructio …
  • The Housing Bank for Trade and Finance:企業の戦略・SWOT・財務分析
    The Housing Bank for Trade and Finance - Strategy, SWOT and Corporate Finance Report Summary The Housing Bank for Trade and Finance - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Recursion Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Recursion Pharmaceuticals Inc (Recursion Pharmaceuticals) is a biotechnology company that develops novel therapies for the treatment of rare genetic diseases. The company’s pipeline products include novel drugs for various diseases such as ataxia-telangiectasia, cerebral cavernous malformati …
  • Yara International ASA:企業の戦略・SWOT・財務分析
    Yara International ASA - Strategy, SWOT and Corporate Finance Report Summary Yara International ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Olympus Corporation (7733)-医療機器分野:企業M&A・提携分析
    Summary Olympus Corporation (Olympus) is a manufacturer of precision machineries and instruments. The company develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and other industrial markets. It offers a wide range of products including digital SLR …
  • Electricite de France SA (EDF)-エネルギー分野:企業M&A・提携分析
    Summary Electricite de France S.A. (EDF) is a state-owned integrated energy company that generates, transmits, distributes and sells electricity; supplies natural gas; and offers energy services such as district heating, thermal energy services and other services. The group generates electricity fro …
  • InspireMD Inc (NSPR):企業の財務・戦略的SWOT分析
    Summary InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for us …
  • Mitsubishi Gas Chemical Co Inc (4182):企業の財務・戦略的SWOT分析
    Mitsubishi Gas Chemical Co Inc (4182) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • China International Water & Electric Corp:企業の戦略的SWOT分析
    China International Water & Electric Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆